OUR MISSION

Our mission is to improve the quality of life for people in pain through novel, cost effective pain assessment tools. 

Our vision is to be first to market with novel pain assessment products and services that improve patient quality of life and are accessible for carers everywhere.

ePAT Apps are revolutionary.

Use of ePAT Apps has international patent clearance.

Smart phone enabled medical Apps are rapidly growing within the Healthcare market.

Clear regulatory approval pathways.

Short time frame to commercialisation.

THE PROBLEM

Pain is often poorly managed particularly in those who are unable to communicate.

Tools used to assess pain are highly subjective and often not used.

As a result, pain often goes undetected and untreated.

Pain is the most common reason that people seek medical assistance.

OUR PROPOSED SOLUTION

A point of care App which utilises facial recognition technology to detect micro­ expressions which are indicative of presence of pain.

These data are combined with non-facial pain cues (vocalisations, movements and behaviours) captured through the App to automatically calculate a pain severity score.

ePAT APP is designed to allow pain assessments to be:

  • Simple
  • Accurate
  • Objective
  • Reproducible

Watch the informative short videos for a clearer understanding on the technology behind ePAT

OUR TARGET MARKET

EVERYONE who cares for ANYONE who cannot self-report their pain

DEMENTIA

  • Dementia is a syndrome in which there is deterioration in memory, thinking, behaviour and the ability to perform everyday activities.
  • Worldwide, 47.5 million people have dementia and there are 7.7 million new cases every year.
  • The number of people with dementia is expected to increase to 75.6 million in 2030 and 135.5 million in 2050.
  • The percentage of people with dementia in the US illustrates the increasing prevalence of dementia with advanced age:
    • dementiabtn25% of those age 71-79
    • 24% of those age 80-89
    • 37% for those age 90 and over
      (Plassman et al, 2007).
  • Huge economic impact; US$ 604 billion per year
  • Dementia is one of the major causes of disability and dependency among older people worldwide.
  • Dementia has physical, psychological, social and economical impact on caregivers, families and society.
  • The high cost of the disease will challenge health systems to deal with the predicted future increase of cases.
  • Dementia is overwhelming not only for the people who have it, but also for their caregivers and families.

ESTIMATED 150 MILLION CARERS FOR PEOPLE WITH DEMENTIA GLOBALLY

Sources: WHO and Dementia Care Central

PRE-VERBAL CHILDREN

  • Pre-verbal children include neonates (aged 0-1 month) and infants and toddlers (1 month- 3 years).
  • Sources of pain in children can include rashes, teething pain, middle ear infections, and, once they become mobile, cuts and abrasions.
  • Currently, diagnosis of pain in pre-verbal children requires consultation with a health care professional as this age group lacks the language ability to describe their pain.
  • Such assessments are not always accurate. For instance, parents often rely on intuitions, assumptions, and personal beliefs in order to assess the child’s pain rather than objective, accurate and adaptable assessment.

4 Babies Born Every second  |  130 million Births per year  |  260 million New parents

OTHER TARGET MARKETS

Patient groups in which the ability to communicate verbally may be impaired, examples include:

  • Delirium (acute change in mental status)market3
  • People who have had a stroke
  • People with intellectual development delay
  • People with acquired brain injury

Additional markets where there is a current need for ePAT technology, examples include:

Tele-Health – Support clinician remote patient assessmentsmarket4

Insurance Claims – Assisting in assessment of personal injury claims

Pharmaceutical Companies – Monitoring tool for clinical trials of pain relief drugs

CLINICAL STUDIES

Validation Study Results

ePAT demonstrated excellent performance compared to the existing Australian standard for pain assessment (Abbey Pain Scale) in patients with dementia.

Pilot validation studies involving three residential aged care homes (Juniper, Brightwater and Bethanie) involving 40 residents with moderate to severe dementia completed May 2016.

raw_all

res_all

ePAT vs Abbey Pain Scale

Patients n = 40  |  Assessments = 354  |  Correlation coefficient = 0.90

OUR PARTNERS

 
partners1
partners2
partners3
partners4
partners5
CurtinUniversityLogo

NEWS & REVIEWS

acsimage1

Mustafa named Gold Disruptor Winner - ACS 2016 Digital Disruptor Awards

ePAT Technologies Scientific Officer recognized  as Gold Disruptor…
foreignaffairs

CSIRO Innovation Fund

The CSIRO Innovation Fund ePAT – real time pain assessment…
governmentfunding

ePAT targeted for Government Innovative Funding scheme

Seaweed that reduces the methane in cow burps and farts, a low-gluten…
acsimage2

Creative Innovation

Emerging Innovators win scholarships to event of the year 60…
sundaytimes

Face videos reveal the hidden pain

WA Business Weekly In the press this weekend - Face videos reveal…
wa_awards2

The 2016 Mitsubishi Corporation WA Innovator of the Year Winners

Mustafa Atee wins Innovator of the Year 2016 Mustafa Atee receives…
acsimage

ACS DIGITAL - 2016 FINALISTS

ACS Digital Disruptors Mustafa Atee is ICT Researcher of the…
channel9image
abcnewsimage

ABC NEWS

An app that recognises when people who cannot communicate verbally…
inciteawardsimage

NATIONAL iAWARDS

NATIONAL iAWARDS FINALISTS Mustafa Atee from Curtin University,…

OUR TEAM

Strong track record in clinical practice, R&D, innovation and commercialisation

<br />
<h3>Philip Daffas<br />
<h3>


Philip Daffas

CEO & Managing Director, MBA, BSc

Philip is a highly accomplished global business leader and people manager with an international career..

<br />
<h3>Prof Jeff Hughes<br />
<h3>


Prof Jeff Hughes

Chief Scientific Officer PhD, MPS

Jeff is a professor in the School of Pharmacy, Curtin University in Western Australia.

<br />
<h3>Dr Kreshnik Hoti<br />
<h3>


Dr Kreshnik Hoti

Senior Research Scientist PhD, MPS

Kreshnik is a registered community and consultant pharmacist with a PhD in Pharmacy..

<br />
<h3>Mustafa Atee<br />
<h3>


Mustafa Atee

Research Scientist MPS, PhD (candidate)

Mustafa is a clinical, community and academic pharmacist. Throughout his 11-year career in pharmacy..

<br />
<h3> Ian Hobson</h3>
<p>


Ian Hobson

Company Secretary

Ian is a chartered accountant and chartered secretary who acts as non-executive director and company secretary to ASX listed..

OUR BOARD

Strong track record in building global businesses, corporate governance and successful commercialisation of novel healthcare

<br />
<h3>John Murray</h3>
<p>


John Murray

Non-Executive Chairman of the Board

John has over 20 years’ experience in private equity and venture capital, and was a co- founder and Managing Partner of Technology Venture Partners;

<br />
<h3>Philip Daffas</h3>
<p>


Philip Daffas

CEO & Managing Director, MBA, BSc

Philip is a highly accomplished global business leader and people manager with an international career..

<br />
<h3>Ross Harricks</h3>
<p>


Ross Harricks

Non-Executive Director, BSc, BEng(Hons), MBA (Distinction)

Ross’ experience in the commercialisation of medical products spans over thirty years and over three continents.

<br />
<h3>Adam Davey</h3>
<p>


Adam Davey

Non-Executive Director

Adam is the Director, Private Clients and Institutional at Patersons Securities.

CONTACT US

Contact Us

SUPPORTED BY:

 
sponsor2
sponsor3
sponsor1
sponsors4